KEYTRUDA cuts death risk by 18% in ovarian cancer, 35% in bladder cancer, and reduces RCC recurrence by 28%, based on Phase 3 KEYNOTE-B96, KEYNOTE-B15, and LITESPARK-022
Written By: Sana Khan BPharm and Samiksha Jadhav BPharm
Reviewed By: Pharmacally Editorial Team
Merck & Co. has announced positive results from three Phase 3 trials evaluating KEYTRUDA in combination regimens across ovarian cancer, muscle-invasive bladder cancer, and renal cell carcinoma (RCC). The studies demonstrated statistically significant reductions in recurrence and death risk, further expanding KEYTRUDA’s role across tumor types and treatment settings.
1] KEYNOTE-B96: KEYTRUDA Plus Paclitaxel ± Bevacizumab in Platinum-Resistant Ovarian Cancer
Trial Overview
- Phase 3 KEYNOTE-B96
- Population: Platinum-resistant recurrent ovarian cancer
- Regimen: KEYTRUDA + paclitaxel ± bevacizumab
- Comparator: Paclitaxel ± bevacizumab
Topline Results
Overall Survival (Key Secondary Endpoint)
- 18% reduction in risk of death HR = 0.82 (95% CI: 0.69–0.97) p = 0.0115
- Median OS- 17.7 months vs 14.0 months
Progression-Free Survival (Primary Endpoint Previously Met)
- 27% reduction in risk of progression or death overall, HR = 0.73
- In PD-L1 CPS ≥1 patients 24% reduction in risk of progression
- 24% reduction in risk of death HR = 0.76
Clinical Significance
Platinum-resistant ovarian cancer remains a high unmet need, with relapse occurring within six months of platinum therapy. The 3.7-month median OS improvement and statistically significant PFS and OS benefits suggest this combination could become a new standard option in this difficult-to-treat population.
2] KEYNOTE-B15: KEYTRUDA Plus Padcev in Muscle-Invasive Bladder Cancer
In the Phase 3 KEYNOTE-B15 trial, KEYTRUDA combined with Padcev demonstrated strong perioperative benefit in cisplatin-eligible patients with muscle-invasive bladder cancer.
Trial Overview
- Phase 3 KEYNOTE-B15
- Population: Cisplatin-eligible MIBC
- Setting: Neoadjuvant + adjuvant (perioperative)
- Comparator: Standard chemotherapy
Topline Results
- 47% reduction in risk of event-free survival (EFS) events
- 35% reduction in risk of death
Clinical Significance
Muscle-invasive bladder cancer carries a substantial risk of recurrence even after radical cystectomy and cisplatin-based chemotherapy. The magnitude of benefit observed in both EFS and OS suggests the combination may redefine perioperative treatment standards.
Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4, frequently expressed in urothelial carcinoma. Combined with PD-1 inhibition, the regimen integrates immune activation with targeted cytotoxic therapy.
3] LITESPARK-022: KEYTRUDA Plus Welireg in Renal Cell Carcinoma
Merck also reported positive findings from the Phase 3 LITESPARK-022 trial evaluating KEYTRUDA in combination with Welireg in renal cell carcinoma.
Trial Overview
- Phase 3 LITESPARK-022
- Population: Patients with renal cell carcinoma
- Endpoint: Disease-free survival / recurrence
Topline Results
- 28% reduction in risk of disease recurrence or death
Clinical Significance
Renal cell carcinoma patients remain at risk of recurrence even after definitive therapy. Belzutifan is a HIF-2α inhibitor that targets hypoxia-inducible pathways involved in tumor growth and angiogenesis. Combining it with pembrolizumab aims to enhance immune-mediated tumor control while inhibiting key oncogenic signaling pathways.
The 28% risk reduction indicates meaningful benefit in reducing recurrence risk in RCC
Strategic Perspective
Across three independent Phase 3 trials:
- KEYNOTE-B96 demonstrated survival benefit in platinum-resistant ovarian cancer.
- KEYNOTE-B15 showed substantial perioperative improvement in muscle-invasive bladder cancer.
- LITESPARK-022 reduced recurrence risk in renal cell carcinoma.
Together, these results reinforce KEYTRUDA’s expanding role from advanced resistant disease settings to earlier-stage, curative-intent strategies across multiple solid tumors.
Regulatory discussions and full data presentations are expected in upcoming scientific forums.
References
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer, 27 February 2026, KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer – Merck.com
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery, 27 February 2026, KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery – Merck.com
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC), 28 February 2026, KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC) – Merck.com
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer, 27 February 2026, https://www.pfizer.com/news/press-release/press-release-detail/padcevtm-keytrudar-cuts-risk-recurrence-or-death-nearly-50
About Writer:
Sana Jamil Khan, BPharm
She is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publication and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.
About Writer:
Samiksha Vikram Jadhav, BPharm
She is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publication and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.